Skip to main content
All lobbying filings

AMGEN, INC.

Lobbying for AMGEN INC

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2025 · District of Columbia · House · Senate · $3,610,000.00 expenses · posted Apr 21, 2025

Official filing document

 Bills named in this filing 10
  • HR 946
    ORPHAN Cures Act
  • HR 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
  • HR 1672
    Maintaining Investments in New Innovation Act
  • HR 2214
    DRUG Act
  • HR 1968
    Full-Year Continuing Appropriations and Extensions Act, 2025
  • SCONRES 7
    An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal ye…
  • HCONRES 14
    Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…
  • HR 1328
    Supply Chain Security and Growth Act of 2025
  • S 1041
    Affordable Prescriptions for Patients Act
  • S 1040
    Drug Competition Enhancement Act
 Lobbying activity 5
Health Issues

Issues related to drug pricing reform -Changes to Public law 117-1769 Inflation Reduction Act -Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Issues related to prohibiting the export of biotechnology to certain foreign entities (BIOCOMPETE) Issues related to direct-to-consumer advertising Issues related to obesity disease awareness and treatment Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to pediatric priority review voucher reauthorization HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Insuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 2214 DRUG Act H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 S.Con.Res.7 - An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. H.Con.Res.14 - Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.

Medicare/Medicaid

Issues related to drug pricing reform Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to obesity disease awareness and treatment Issues related to bone disease awareness and treatment HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Insuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 S.Con.Res.7 - An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. H.Con.Res.14 - Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.

Taxation/Internal Revenue Code

Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act Issues related to Puerto Rico Issues related to OECD negotiations on the taxation of global income HR 1328 Supply Chain Security and Growth Act of 2025

Copyright/Patent/Trademark

Federal Trade Commission related issues, no specific bill Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS waiver, no specific bill Issues related to patent thickets/product hopping Issues related to obviousness/ double patenting Issues related to prohibiting the export of biotechnology to certain foreign entities (BIOCOMPETE) Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patients that claim biological products, and for other purposes. S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.

Tariff (miscellaneous tariff bills)

Issues related to tariffs

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem